{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Fcb8f34fe-4d61-4cf3-bd0f-4dfaf11517eb","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/cb8f34fe-4d61-4cf3-bd0f-4dfaf11517eb\"></iframe>","title":"Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer","description":"\n        <p>Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials  investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.</p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/InsideTheIssue2024/ADCsmBC\" rel=\"nofollow\">here</a></p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/4b9f90cd-a7d9-483b-91c6-3314090c1de5/cover.jpg"}